Scout Investments Inc. Sells 7,682 Shares of PRA Health Sciences Inc (NASDAQ:PRAH)

Share on StockTwits

Scout Investments Inc. lessened its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 93,795 shares of the medical research company’s stock after selling 7,682 shares during the quarter. Scout Investments Inc. owned 0.14% of PRA Health Sciences worth $9,307,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Pearl River Capital LLC bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $40,000. Steward Partners Investment Advisory LLC bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $49,000. Advisor Group Inc. lifted its holdings in shares of PRA Health Sciences by 12.3% in the 2nd quarter. Advisor Group Inc. now owns 1,296 shares of the medical research company’s stock worth $129,000 after acquiring an additional 142 shares during the last quarter. Machina Capital S.A.S. bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $184,000. Finally, Sciencast Management LP bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $208,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

PRAH stock traded up $2.03 during trading on Wednesday, hitting $97.11. The company had a trading volume of 5,953 shares, compared to its average volume of 548,864. The firm has a market capitalization of $6.29 billion, a P/E ratio of 24.60, a PEG ratio of 1.33 and a beta of 1.12. PRA Health Sciences Inc has a 52-week low of $82.12 and a 52-week high of $121.98. The company has a 50 day simple moving average of $100.24 and a 200-day simple moving average of $97.90. The company has a quick ratio of 0.99, a current ratio of 0.99 and a debt-to-equity ratio of 1.11.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.11. The company had revenue of $763.31 million for the quarter, compared to the consensus estimate of $764.95 million. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.00 EPS. Sell-side analysts forecast that PRA Health Sciences Inc will post 4.65 earnings per share for the current year.

Several research firms have recently issued reports on PRAH. Barclays raised their target price on shares of PRA Health Sciences from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Svb Leerink reaffirmed a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. Leerink Swann started coverage on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 price target on the stock. Finally, Goldman Sachs Group started coverage on shares of PRA Health Sciences in a research note on Thursday, September 19th. They issued a “buy” rating and a $126.00 price target on the stock. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $115.86.

In other PRA Health Sciences news, major shareholder Fund Holdings L.P. Kkr sold 6,666,684 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $97.41, for a total transaction of $649,401,688.44. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.95% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: P/E Growth (PEG)

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.